New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 6, 2014
08:00 EDTBSXBoston Scientific upgraded at Oppenheimer
As previously reported, Oppenheimer upgraded Boston Scientific to Overweight from Equal Weight. The firm upgraded shares to reflect pipeline acceleration and margin improvement in cardiology. Price target is $15.
News For BSX From The Last 14 Days
Check below for free stories on BSX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 23, 2014
17:10 EDTBSXBoston Scientific receives CE Mark for Agent Drug Coated Balloon
Subscribe for More Information
15:30 EDTBSXNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's market open, with earnings consensus, include Ford (F), consensus 36c; General Motors (GM), consensus 58c; Potash (POT), consensus 46c; Caterpillar (CAT), consensus $1.52; 3M (MMM), consensus $1.91; Union Pacific (UNP), consensus $1.43; Bristol-Myers Squibb (BMY), consensus 44c; Eli Lilly (LLY), consensus 65c; Celgene (CELG), consensus 89c; Precision Castparts (PCP), consensus $3.35; Raytheon (RTN), consensus $1.59; Noble Energy (NBL), consensus 79c; Hershey (HSY), consensus 76c; Southwest Airlines (LUV), consensus 61c; Boston Scientific (BSX), consensus 19c; JetBlue (JBLU), consensus 19c.
July 22, 2014
08:25 EDTBSXBoston Scientific risk/reward favorable into Q2 results, says RBC Capital
Subscribe for More Information
July 21, 2014
16:38 EDTBSXBoston Scientific receives FDA approval for REBEL Platinum Stent system
Subscribe for More Information
July 14, 2014
19:19 EDTBSXBoston Scientific receives CE Mark for 25 mm Lotus Valve System
Subscribe for More Information
09:02 EDTBSXBoston Scientific receives CE mark for Ranger drug-coated balloon
Boston Scientific has received CE Mark for the Ranger Paclitaxel-Coated PTA Balloon Catheter. The technology is now in full European market launch. The Balloon provides physicians with an additional option to treat peripheral artery disease, delivering an anti-stenotic drug to diseased vascular tissue while leaving no permanent implant behind.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use